MA39735A - Dosage de préparations de cabozantinib - Google Patents

Dosage de préparations de cabozantinib

Info

Publication number
MA39735A
MA39735A MA039735A MA39735A MA39735A MA 39735 A MA39735 A MA 39735A MA 039735 A MA039735 A MA 039735A MA 39735 A MA39735 A MA 39735A MA 39735 A MA39735 A MA 39735A
Authority
MA
Morocco
Prior art keywords
cabozantinib
formulations
dosing
dicarboxamide
methyloxy
Prior art date
Application number
MA039735A
Other languages
English (en)
Inventor
Dana T Aftab
Steven Lacy
Sriram Naganathan
Wei Xu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA39735A publication Critical patent/MA39735A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne l'administration de diverses préparations pharmaceutiques de n-(4-{[6,7-bis(méthyloxy)quinolin-4-yl]oxy}phényl)-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide (le cabozantinib), d'un inhibiteur de c-met et de ses métabolites, afin d'obtenir des effets pharmacocinétiques et pharmacodynamiques souhaités.
MA039735A 2014-03-17 2015-03-17 Dosage de préparations de cabozantinib MA39735A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461954352P 2014-03-17 2014-03-17

Publications (1)

Publication Number Publication Date
MA39735A true MA39735A (fr) 2017-01-25

Family

ID=52811227

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039735A MA39735A (fr) 2014-03-17 2015-03-17 Dosage de préparations de cabozantinib

Country Status (7)

Country Link
US (3) US10159666B2 (fr)
EP (1) EP3119476A1 (fr)
JP (1) JP6666849B2 (fr)
CN (1) CN106255499A (fr)
EA (1) EA201691850A1 (fr)
MA (1) MA39735A (fr)
WO (1) WO2015142928A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52754B2 (sr) 2009-01-16 2022-08-31 Exelixis Inc Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2826751C (fr) 2011-02-10 2021-05-18 Exelixis, Inc. Procedes de synthese de quinoleines et compositions pharmaceutiques les incluant
GEP20196995B (en) * 2013-03-15 2019-07-25 Inc Exelixis Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
EP3738952A1 (fr) 2014-02-14 2020-11-18 Exelixis, Inc. Formes solides cristallines du n-{4-[(6,7-diméthoxyquinolin-4-yl)oxy]phényl}-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
WO2015142928A1 (fr) 2014-03-17 2015-09-24 Exelixis, Inc. Dosage de préparations de cabozantinib
MA40386A (fr) * 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
EA034992B1 (ru) 2014-08-05 2020-04-15 Экселиксис, Инк. Комбинации лекарственных средств для лечения множественной миеломы
CN112028825B (zh) * 2015-04-07 2025-03-14 广东众生睿创生物科技有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
EP3442531A1 (fr) 2016-04-15 2019-02-20 Exelixis, Inc. Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN107951850A (zh) * 2017-12-20 2018-04-24 深圳万乐药业有限公司 一种苹果酸卡博替尼片的制备方法
MY210421A (en) 2018-01-26 2025-09-22 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
EP4658271A1 (fr) 2023-01-31 2025-12-10 Handa Oncology, LLC Compositions de cabozantinib améliorées et procédés d'utilisation
WO2025079089A1 (fr) * 2023-10-09 2025-04-17 Msn Laboratories Private Limited, R&D Center Composition pharmaceutique de cabozantinib
WO2025196845A1 (fr) * 2024-03-22 2025-09-25 Meishi Pharma Services Pvt. Ltd. Formulations améliorées de cabozantinib

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2392565B1 (fr) 2003-09-26 2014-03-19 Exelixis, Inc. Modulateurs de c-Met et procédés d'utilisation
CA2603748A1 (fr) 2005-04-06 2006-10-12 Exelixis, Inc. Modulateurs c-met modulators et procedes d'utilisation
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
CN102282134B (zh) 2008-11-13 2015-04-01 埃克塞里艾克西斯公司 喹啉衍生物制备方法
WO2010065838A1 (fr) 2008-12-04 2010-06-10 Exelixis, Inc. Procédés de préparation de dérivés de quinoléine
RS52754B2 (sr) 2009-01-16 2022-08-31 Exelixis Inc Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
EP2454238A1 (fr) 2009-07-17 2012-05-23 Exelixis, Inc. Formes cristallines du n [3 fluoro-4-({méthyloxy)-7-[(3-morpholin-4-yl- propyl)oxy]quinoléin-4-yl}oxy)phényl]-n'-(4-fluorophényl)cyclopropane- 1,1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CN102933551A (zh) 2010-03-12 2013-02-13 埃克塞里艾克西斯公司 N-[3-氟-4-({6-(甲氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺的水合结晶形式
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
KR20180056807A (ko) 2010-07-16 2018-05-29 엑셀리시스, 인코포레이티드 C-met 조절제 약제학적 조성물
EP2593091A1 (fr) 2010-07-16 2013-05-22 Exelixis, Inc. Compositions pharmaceutiques modulatrices de c-met
PL2621481T5 (pl) 2010-09-27 2023-03-13 Exelixis, Inc. Podwójne inhibitory MET i VEGF do leczenia opornego na kastrację raka prostaty i osteoblastycznych przerzutów do kości
JP2013537918A (ja) 2010-09-27 2013-10-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
WO2012044574A1 (fr) 2010-09-27 2012-04-05 Exelixis, Inc. Inhibiteurs de met et vegf à double effet pour le traitement du cancer de la prostate résistant à la castration et des métastases osseuses ostéoblastiques
JP2013543011A (ja) 2010-11-22 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 癌の治療法
CA2826751C (fr) 2011-02-10 2021-05-18 Exelixis, Inc. Procedes de synthese de quinoleines et compositions pharmaceutiques les incluant
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
JP2014513129A (ja) 2011-05-02 2014-05-29 エクセリクシス， インク． 癌および骨癌疼痛の治療方法
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
EP2758057B1 (fr) 2011-09-22 2017-05-31 Exelixis, Inc. Méthode de traitement de l'ostéoporose
CN104395284A (zh) 2011-10-20 2015-03-04 埃克塞里艾克西斯公司 制备喹啉衍生物的方法
KR20140088610A (ko) 2011-11-08 2014-07-10 엑셀리시스, 인코포레이티드 암을 치료하기 위한 met 및 vegf의 이중 저해제
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
WO2014039971A1 (fr) 2012-09-07 2014-03-13 Exelixis, Inc. Inhibiteurs de met, vegfr et ret pour l'utilisation dans le traitement d'un adénocarcinome du poumon
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
GEP20196995B (en) * 2013-03-15 2019-07-25 Inc Exelixis Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
CN108472242A (zh) 2013-04-04 2018-08-31 埃克塞里艾克西斯公司 治疗癌症的药物组合
EP3738952A1 (fr) 2014-02-14 2020-11-18 Exelixis, Inc. Formes solides cristallines du n-{4-[(6,7-diméthoxyquinolin-4-yl)oxy]phényl}-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
WO2015142928A1 (fr) 2014-03-17 2015-09-24 Exelixis, Inc. Dosage de préparations de cabozantinib
EP3906921A1 (fr) 2014-04-25 2021-11-10 Exelixis, Inc. Procédé de traitement de l'adénocarcinome pulmonaire
MA40386A (fr) 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
EA034992B1 (ru) 2014-08-05 2020-04-15 Экселиксис, Инк. Комбинации лекарственных средств для лечения множественной миеломы
US20170224670A1 (en) 2014-10-14 2017-08-10 Exelixis, Inc. Drug Combination to Treat Melanoma

Also Published As

Publication number Publication date
EP3119476A1 (fr) 2017-01-25
US20190076420A1 (en) 2019-03-14
US20200163954A1 (en) 2020-05-28
JP6666849B2 (ja) 2020-03-18
WO2015142928A1 (fr) 2015-09-24
JP2017507995A (ja) 2017-03-23
CN106255499A (zh) 2016-12-21
US10159666B2 (en) 2018-12-25
US20170087143A1 (en) 2017-03-30
EA201691850A1 (ru) 2016-12-30

Similar Documents

Publication Publication Date Title
MA39735A (fr) Dosage de préparations de cabozantinib
GEAP201913960A (en) Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
MY192084A (en) Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
HUE057877T2 (hu) Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
MY196014A (en) Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride
EP3310343A4 (fr) Compositions implantables pour administration de médicaments et méthodes d'utilisation desdites compositions
MY176176A (en) Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
EA201792591A1 (ru) Фармацевтические препараты
SG10201902203VA (en) Eutectic formulations of cyclobenzaprine hydrochloride
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
EA201890532A1 (ru) Новые аннелированные бензамиды
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
MX356789B (es) Composición de difenidol de liberación prolongada.
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
EP3733243A4 (fr) Procédé d'administration de médicament
PH12018501758A1 (en) Oritavancin formulations
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
SG11202104499RA (en) Pharmaceutical formulations for subcutaneous administration
IL261929B (en) Stable pharmaceutical preparations for topical administration and their use
HK1233569A1 (en) Dosing of cabozantinib formulations